Press Releases


Aladdin Healthcare Technologies SE approved for Listing on OTCQB in the USA

BERLIN/LONDON November 24, 2021 - Aladdin Healthcare Technologies SE (“Aladdin”, ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, announces that it has gained approval from OTC Markets Group to have the company’s shares listed on the OTCBQ market. The company’s shares will be traded under the symbol ALDNF. Aladdin has agreed to join OTCQB on November 29, 2021.

The OTCQB, also called “The Venture Market,” is the middle tier of the over the counter (OTC) market for U.S. stocks. The listing will increase the attractiveness of the Aladdin share and facilitate greater attention from investors within the world’s largest technology market, the USA, whilst also allowing foreign investors to participate in the trading of the shares. The existing listing on the Düsseldorf and the Frankfurt Stock Exchange will continue. The company then intends, with further expansion, to move up to OTCQX and over the medium term to the Nasdaq.

“With the American listing, we are now moving into the world’s best capital market for healthcare technology taking a decisive step to accompany our rapidly growing business. As a leading developer of AI healthcare diagnostics and drug discovery applications for age-related diseases, we see it as a great opportunity to present our business model and its growth prospects to investors who are attracted to innovative companies with rapid growth potential,” said Wade Menpes-Smith, CEO from Aladdin Healthcare Technologies SE.

About Aladdin Healthcare Technologies SE

Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets aged related disease including a significant focus on Alzheimer’s disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose aged related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used to by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link:

For further information
Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696

Contact Press
CROSS ALLIANCE communication GmbH
Susan Hoffmeister
Phone +49 89 1250 90330